107 related articles for article (PubMed ID: 38815166)
1. Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion.
Pham LC; Weller L; Gann CN; Schumacher KM; Vlassak S; Swanson T; Highsmith K; O'Brien BJ; Nash S; Aaroe A; de Groot JF; Majd NK
Oncologist; 2024 May; ():. PubMed ID: 38815166
[TBL] [Abstract][Full Text] [Related]
2. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J; Friese-Hamim M; Clark A; Schadt O; Walter-Bausch G; Stroh C; Johne A; Karachaliou N; Blaukat A
Mol Cancer Ther; 2023 Jul; 22(7):833-843. PubMed ID: 36999986
[TBL] [Abstract][Full Text] [Related]
3. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
Zeng AL; Yan W; Liu YW; Wang Z; Hu Q; Nie E; Zhou X; Li R; Wang XF; Jiang T; You YP
Oncogene; 2017 Sep; 36(38):5369-5381. PubMed ID: 28504721
[TBL] [Abstract][Full Text] [Related]
4. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
5. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
6. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
[TBL] [Abstract][Full Text] [Related]
7. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S
Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
9. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
10. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
[TBL] [Abstract][Full Text] [Related]
11. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Friese-Hamim M; Clark A; Perrin D; Crowley L; Reusch C; Bogatyrova O; Zhang H; Crandall T; Lin J; Ma J; Bachner D; Schmidt J; Schaefer M; Stroh C
Lung Cancer; 2022 Jan; 163():77-86. PubMed ID: 34942492
[TBL] [Abstract][Full Text] [Related]
12. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).
Yalamarty SSK; Filipczak N; Li X; Subhan MA; Parveen F; Ataide JA; Rajmalani BA; Torchilin VP
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046777
[TBL] [Abstract][Full Text] [Related]
14. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
15. Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With
Ninomaru T; Okada H; Fujishima M; Irie K; Fukushima S; Hata A
JTO Clin Res Rep; 2021 Mar; 2(3):100145. PubMed ID: 34590003
[TBL] [Abstract][Full Text] [Related]
16. Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma.
Alafate W; Li X; Zuo J; Zhang H; Xiang J; Wu W; Xie W; Bai X; Wang M; Wang J
CNS Neurosci Ther; 2020 Apr; 26(4):475-485. PubMed ID: 32187449
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.
Lee JK; Joo KM; Lee J; Yoon Y; Nam DH
Onco Targets Ther; 2014; 7():1933-44. PubMed ID: 25364264
[TBL] [Abstract][Full Text] [Related]
19. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
